GlassScriptPhysician profile
Paul H Davis
NPI 1710980164
$18,286.86
in general payments reported to CMS, 2019-2025
59 companies · $2,268 in 2025
The $2,268 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,149 · 2020: $2,667 · 2021: $3,416 · 2022: $1,866 · 2023: $2,241 · 2024: $2,680 · 2025: $2,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,187.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,864.65 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,305.13 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $1,298.91 | 2019-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $1,217.78 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,208.16 | 2019-2025 | Ubrelvy, Qulipta, Linzess |
| Astrazeneca Pharmaceuticals LP | $1,203.56 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $688.29 | 2019-2025 | Xarelto, Spravato |
| Supernus Pharmaceuticals, INC. | $667.98 | 2020-2024 | Qelbree, Qelbree |
| Amarin Pharma, INC. | $591.45 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $550.87 | 2019-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $509.18 | 2019-2024 | |
| Radius Health, INC. | $319.38 | 2019-2025 | Tymlos |
| Teva Pharmaceuticals USA, INC. | $309.70 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $290.98 | 2021-2024 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.